Crossmark

Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation

Crossref DOI link: https://doi.org/10.1007/s12471-018-1119-z

Published Online: 2018-05-09

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Vugt, S. P. G.

Brouwer, M. A.
License Information

Text and Data Mining valid from 2018-05-09
More Information

Article History

First Online: 9 May 2018

Conflict of interest

: S.P.G. van Vugt has received consulting fees/honorariums from Bayer, Boehringer Ingelheim, Bristol-Meyers-Squibb/Pfizer and Daiichi Sankyo and M.A. Brouwer has received consulting fees/honorariums from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Meyers-Squibb/Pfizer and Daiichi Sankyo.